[Study on the in vitro and in vivo thrombolytic efficacy of bispecific antifibrin-antiurokinase monoclonal antibodies].
OBJECTIVE
To evaluate the thrombolytic efficacy of bispecfic antifibrin-antiurokinase monoclonal antibodies.


METHODS
Murine hybrid hybridomas secreting bispecific monoclonal antibodies (bsMcAbs) were prepared by fusing a mutant hybridomas secreting antifibrin McAbs with spleen cells of murine immunized with urokinase. The binding power of bsMcAbs with fibrin or urokinase was determined by ELISA method. The in vitro thrombolytic efficacy was measured by the dissolving rate of 131I-plasma clot. The in vivo thrombolytic efficacy was measured by using the rabbit jugular vein thrombus model.


RESULTS
8 strains of bsMcAbs have been obtained. ELISA experiments showed that bsMcAbs have very strong binding power with fibrin or urokinase. The bsMcAbs bound with urokinase increased the in vitro thrombolytic efficacy of urokinase by 15.5%. The in vivo thrombolytic efficacy of bsMcAbs bound with urokinase was 1.6-2.1 times as high as urokinase.


CONCLUSIONS
Monoclonal antibody-directed thrombolytic agents have advantages of high specificity and strong local thrombolytic efficacy. It is well worth going on further study.
Yuan
H
H
Institute of Radiation Medicine, CAMS and PUMC, Tianjin, 300192.
Lin
H
H
Zhu
X
X
Zhang
Y
Y
Zhang
X
X
D000818:Animals; D018033:Antibodies, Bispecific / Q000096:biosynthesis / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D002459:Cell Fusion; D005337:Fibrin / Q000276:immunology*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006825:Hybridomas / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D011817:Rabbits; D013154:Spleen / Q000166:cytology; D014568:Urokinase-Type Plasminogen Activator / Q000276:immunology*; D020246:Venous Thrombosis / Q000188:drug therapy
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D005337:Fibrin; D014568:Urokinase-Type Plasminogen Activator